Results 271 to 280 of about 3,307,905 (304)
Some of the next articles are maybe not open access.
Current Opinion in Pharmacology, 2019
Cancer vaccines based on synthetic peptides are a safe, well-tolerated immunotherapy able to specifically stimulate tumor-reactive T cells. However, their clinical efficacy does not approach that achieved with other immunotherapies such as immune checkpoint blockade.
Calvo Tardon, Marta +4 more
openaire +4 more sources
Cancer vaccines based on synthetic peptides are a safe, well-tolerated immunotherapy able to specifically stimulate tumor-reactive T cells. However, their clinical efficacy does not approach that achieved with other immunotherapies such as immune checkpoint blockade.
Calvo Tardon, Marta +4 more
openaire +4 more sources
Immunosenescence and cancer vaccines
Cancer Immunology, Immunotherapy, 2009Experimental and clinical data demonstrate that ageing is associated with the gradual deterioration of the immune system, generally referred to as immunosenescence. Age-related immune dysfunction may have an impact not only on the incidence of cancer, but also on the preventive and therapeutic approaches, which are based on immune system activation ...
openaire +2 more sources
Current Opinion in Immunology, 2006
The immunological bases of current approaches to therapeutic cancer vaccination (or 'vacci-treatment') have been established for a decade or longer. The new developments lie mostly in the lessons learnt from clinical testing of these approaches. Three lessons are particularly worthy of note.
openaire +2 more sources
The immunological bases of current approaches to therapeutic cancer vaccination (or 'vacci-treatment') have been established for a decade or longer. The new developments lie mostly in the lessons learnt from clinical testing of these approaches. Three lessons are particularly worthy of note.
openaire +2 more sources
Cancer Investigation, 2002
The revelation that immune cytolytic and helper T-cells recognize intracellularly degraded peptides processed via the proteosome apparatus, inserted into the endoplasmic reticulum and transported to the surface for association with major histocompatibility locus (MHC) molecules on specialized antigen-presenting cells has revolutionized the cancer ...
openaire +2 more sources
The revelation that immune cytolytic and helper T-cells recognize intracellularly degraded peptides processed via the proteosome apparatus, inserted into the endoplasmic reticulum and transported to the surface for association with major histocompatibility locus (MHC) molecules on specialized antigen-presenting cells has revolutionized the cancer ...
openaire +2 more sources
A vaccine for colorectral cancer
Trends in Immunology, 2001Colorectal cancer is one of the four most prevalent cancers worldwide. It is estimated that in the USA this year, 135 400 people will be diagnosed with and 56 700 people will die from this disease. Life expectancy for stage IV disease, which might affect as many as 50 000 individuals in the USA this year, is seven and a half months.At the 37th Annual ...
openaire +2 more sources
Cancer therapy and vaccination
Journal of Immunological Methods, 2012Cancer remains one of the leading causes of death worldwide, both in developed and in developing nations. It may affect people at all ages, even fetuses, but the risk for most varieties increases with age. Current therapeutic approaches which include surgery, chemotherapy and radiotherapy are associated with adverse side effects arising from lack of ...
openaire +2 more sources
COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety
Nature Reviews Clinical Oncology, 2022John Haanen +2 more
exaly
Metal-based nano-vaccines for cancer immunotherapy
Coordination Chemistry Reviews, 2022Yumiao Zhang, Jiexin Li
exaly